FABP1 and acute kidney injury: A prospective, observational study of 42 multidrug-resistant septic patients treated with colistimethate sodium demonstrated that subclinical AKI defined as urinary L-FABP more than 10.5 ng/mL was detected in 45.2% and 54.8% on days 5 and 7 of treatment, respectively.